- Home
- AB vs GKOS Comparison
AB vs GKOS Comparison
Compare AB & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AB
- GKOS
- Stock Information
- Founded
- AB 1987
- GKOS 1998
- Country
- AB United States
- GKOS United States
- Employees
- AB N/A
- GKOS N/A
- Industry
- AB Investment Managers
- GKOS Medical/Dental Instruments
- Sector
- AB Finance
- GKOS Health Care
- Exchange
- AB Nasdaq
- GKOS Nasdaq
- Market Cap
- AB 4.5B
- GKOS 5.4B
- IPO Year
- AB 1988
- GKOS 2015
- Fundamental
- Price
- AB N/A
- GKOS $87.33
- Analyst Decision
- AB Hold
- GKOS Strong Buy
- Analyst Count
- AB 5
- GKOS 13
- Target Price
- AB $40.40
- GKOS $121.46
- AVG Volume (30 Days)
- AB 146.1K
- GKOS 826.0K
- Earning Date
- AB 10-23-2025
- GKOS 10-29-2025
- Dividend Yield
- AB 8.48%
- GKOS N/A
- EPS Growth
- AB 17.05
- GKOS N/A
- EPS
- AB 3.37
- GKOS N/A
- Revenue
- AB N/A
- GKOS $432,953,000.00
- Revenue This Year
- AB N/A
- GKOS $28.90
- Revenue Next Year
- AB $7.42
- GKOS $25.57
- P/E Ratio
- AB $11.47
- GKOS N/A
- Revenue Growth
- AB N/A
- GKOS 26.70
- 52 Week Low
- AB $32.28
- GKOS $77.10
- 52 Week High
- AB $43.30
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- AB 51.86
- GKOS 47.37
- Support Level
- AB $37.25
- GKOS $83.77
- Resistance Level
- AB $38.90
- GKOS $89.29
- Average True Range (ATR)
- AB 0.60
- GKOS 3.01
- MACD
- AB 0.13
- GKOS 0.55
- Stochastic Oscillator
- AB 75.48
- GKOS 57.25
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (42%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of June 2025, the company had $829 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (41%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.